Avanos Medical AVNS Change in net unrealized gain (loss) on derivative instruments
Change in net unrealized gain (loss) on derivative instruments at other companies
Other financials
Where this comes from
Reported directly by Avanos Medical in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent.
The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avanos Medical's change in net unrealized gain (loss) on derivative instruments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avanos Medical's change in net unrealized gain (loss) on derivative instruments?
- Avanos Medical (AVNS) reported change in net unrealized gain (loss) on derivative instruments of $1.5M in Q1 2026.
- How has Avanos Medical's change in net unrealized gain (loss) on derivative instruments changed year-over-year?
- Avanos Medical's change in net unrealized gain (loss) on derivative instruments increased by 1600.0% year-over-year, from -$100K to $1.5M.
- What does change in net unrealized gain (loss) on derivative instruments mean?
- Measures the change in the fair value of derivative instruments designated as cash flow hedges that are effective in offsetting variability in cash flows. This provides insight into the company's exposure to market risks such as interest rate or commodity price fluctuations.